Spartalizumab, mDCF (Docetaxel, Cisplatin and 5-fluorouracil) and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma. A Phase IIA Study
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Spartalizumab (Primary)
- Indications Anal cancer; Carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SPARTANA
- 21 Dec 2023 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
- 21 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Jun 2025.
- 25 May 2023 Planned number of patients changed from 47 to 34.